ANIK - Anika Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5774.74M
Enterprise Value 3656.36M
Trailing P/E 27.55
Forward P/E 141.33
PEG Ratio (5 yr expected) 13.15
Price/Sales (ttm)7.12
Price/Book (mrq)3.09
Enterprise Value/Revenue 36.03
Enterprise Value/EBITDA 615.65

Trading Information

Stock Price History

Beta (3Y Monthly) 1.18
52-Week Change 333.79%
S&P500 52-Week Change 3-0.33%
52 Week High 357.95
52 Week Low 329.01
50-Day Moving Average 347.94
200-Day Moving Average 338.50

Share Statistics

Avg Vol (3 month) 3189.81k
Avg Vol (10 day) 3160.67k
Shares Outstanding 514.21M
Float 13.45M
% Held by Insiders 13.86%
% Held by Institutions 191.91%
Shares Short (Jul 31, 2019) 43.29M
Short Ratio (Jul 31, 2019) 413.35
Short % of Float (Jul 31, 2019) 431.42%
Short % of Shares Outstanding (Jul 31, 2019) 423.86%
Shares Short (prior month Jun 28, 2019) 43.23M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 26.87%
Operating Margin (ttm)33.08%

Management Effectiveness

Return on Assets (ttm)8.14%
Return on Equity (ttm)11.76%

Income Statement

Revenue (ttm)108.88M
Revenue Per Share (ttm)7.70
Quarterly Revenue Growth (yoy)-0.40%
Gross Profit (ttm)74.28M
EBITDA 41.95M
Net Income Avi to Common (ttm)29.26M
Diluted EPS (ttm)2.04
Quarterly Earnings Growth (yoy)-6.50%

Balance Sheet

Total Cash (mrq)141.45M
Total Cash Per Share (mrq)10.26
Total Debt (mrq)23.07M
Total Debt/Equity (mrq)9.19
Current Ratio (mrq)18.28
Book Value Per Share (mrq)18.20

Cash Flow Statement

Operating Cash Flow (ttm)34.79M
Levered Free Cash Flow (ttm)29.9M